Literature DB >> 466744

Comparison of aflatoxin B1 and aflatoxin G1 binding to cellular macromolecules in vitro, in vivo and after peracid oxidation; characterisation of the major nucleic acid adducts.

R C Garner, C N Martin, J R Smith, B F Coles, M R Tolson.   

Abstract

A comparison between [14C]aflatoxin B1 (AFB1) and [14C]aflatoxin G1 (AFG1) binding to rat liver and kidney cellular macromolecules has shown AFG1-DNA and-ribosomal RNA binding to be lower in both organs. For both mycotoxins more was bound to nucleic acids than to protein. Two hours after intraperitoneal injection (60 microgram/100 g) of [14C] AFB1, 40 ng, 151 ng/mg. Loss of radioactivity bound to liver DNA for both [14C]AFB1 and protein respectively and for [14C]AFG1 the respective figures were 10, 7 and 1 ng/mg. Loss of liver bound radioactivity to DNA for both [14C]AFG1 and [14C]AFG1 appeared to be biphasic indicating that an enzymic DNA repair process may be operating. In vitro binding studies also showed less AFG1 was bound to exogenous DNA after microsomal activation than AFB1. This difference was not a result of differences in the chemical reactivity of the "ultimate" electrophilic species, the respective expoxides, since chemical activation studies using 3-chloroperbenzoic acid showed similar amounts of AFG1 and AFB1 to be converted to the epoxides and to bind to DNA. Studies on the distribution coefficients of the two mycotoxins showed AFB1 to be more lipophilic than AFG1 and this may be an important factor in determining the weaker carcinogenicity of the latter compound. Characterisation of the major AFG1-DNA adduct formed in vitro, in vivo and after peracid oxidation showed it to have the structure trans-9,10-dihydro-9-(7-guanyl)-10-hydroxy-aflatoxin G1. This adduct is similar to that obtained from AFB1 by activation in vivo, in vitro and after peracid oxidation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466744     DOI: 10.1016/0009-2797(79)90093-0

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

1.  Intercellular variation in levels of adducts of aflatoxin B1 and G1 in DNA from rat tissues: a quantitative immunocytochemical study.

Authors:  C P Wild; R Montesano; J Van Benthem; E Scherer; L Den Engelse
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Some mass-spectral and n.m.r. analytical studies of a glutathione conjugate of aflatoxin B1.

Authors:  E J Moss; D J Judah; M Przybylski; G E Neal
Journal:  Biochem J       Date:  1983-01-15       Impact factor: 3.857

3.  In vitro reactions of aflatoxin B1-adducted DNA.

Authors:  J D Groopman; R G Croy; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

4.  Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis.

Authors:  S Sinha; C Webber; C J Marshall; M A Knowles; A Proctor; N C Barrass; G E Neal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

5.  DNA binding, adduct characterisation and metabolic activation of aflatoxin B1 catalysed by isolated rat liver parenchymal, Kupffer and endothelial cells.

Authors:  B Schlemper; J Harrison; R C Garner; F Oesch; P Steinberg
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

6.  Dose dependency of aflatoxin B1 binding on human high molecular weight DNA in the activation of proto-oncogene.

Authors:  S S Yang; J V Taub; R Modali; W Vieira; P Yasei; G C Yang
Journal:  Environ Health Perspect       Date:  1985-10       Impact factor: 9.031

7.  Quantitative predictability of carcinogenicity of the covalent binding index of chemicals to DNA: comparison of the in vivo and in vitro assays.

Authors:  M Taningher; G Saccomanno; L Santi; S Grilli; S Parodi
Journal:  Environ Health Perspect       Date:  1990-03       Impact factor: 9.031

8.  Does aflatoxin exposure in the United Kingdom constitute a cancer risk?

Authors:  J C Harrison; M Carvajal; R C Garner
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.